Small cell carcinoma (SCC) is a rare tumor predominantly found in the lungs, with only 5% occurring outside the pulmonary system. Despite its common occurrence in the cervix, SCC can also develop in the ovaries, endometrium, vagina, and vulva. Primary carcinoma of the Bartholin's gland (BGC) represents a minute fraction of gynecological cancers, often presenting diagnostic challenges due to its deep-seated location. We present the case of a 43-year-old menopausal patient with familial cancer predisposition. She presented with a localized mass in the right Bartholin's gland and underwent excision surgery. Histological analysis confirmed a highly aggressive neuroendocrine carcinoma morphologically consistent with small cell neuroendocrine carcinoma. The patient underwent radiochemotherapy with cisplatin and etoposide, followed by pelvic and inguinal radiotherapy and vulvar brachytherapy. Imaging revealed metastatic lymph node dissemination, necessitating aggressive treatment. In conclusion, SCC of the BG is a rare and aggressive malignancy requiring multidisciplinary management for optimal outcomes. Further research is needed to establish standardized treatment protocols and improve prognosis.
%0 Journal Article
%1 hajar2024small
%A Hajar, Medyouni
%A Jihane, Chouef
%A Oumaima, Siyouri
%A Samia, El Hakym
%A Samia, Mhirech
%A Lamiae, Amaadour
%A Karima, Oualla
%A Zineb, Benbrahim
%A Samia, Arifi
%A Nawfel, Mellas
%D 2024
%J African Journal of Medicine and Pharma Research
%K carcinoma cisplatin etoposide radiochemotherapy
%N 1
%P 1-4
%R https://doi.org/10.5281/zenodo.10971995
%T Small Cell Neuroendocrine Carcinoma of Bartholin's Gland: A Case Report
%U https://africanjmpr.com/docs/2024/jan-june-2024/AJMPR-01.pdf
%V 2
%X Small cell carcinoma (SCC) is a rare tumor predominantly found in the lungs, with only 5% occurring outside the pulmonary system. Despite its common occurrence in the cervix, SCC can also develop in the ovaries, endometrium, vagina, and vulva. Primary carcinoma of the Bartholin's gland (BGC) represents a minute fraction of gynecological cancers, often presenting diagnostic challenges due to its deep-seated location. We present the case of a 43-year-old menopausal patient with familial cancer predisposition. She presented with a localized mass in the right Bartholin's gland and underwent excision surgery. Histological analysis confirmed a highly aggressive neuroendocrine carcinoma morphologically consistent with small cell neuroendocrine carcinoma. The patient underwent radiochemotherapy with cisplatin and etoposide, followed by pelvic and inguinal radiotherapy and vulvar brachytherapy. Imaging revealed metastatic lymph node dissemination, necessitating aggressive treatment. In conclusion, SCC of the BG is a rare and aggressive malignancy requiring multidisciplinary management for optimal outcomes. Further research is needed to establish standardized treatment protocols and improve prognosis.
@article{hajar2024small,
abstract = {Small cell carcinoma (SCC) is a rare tumor predominantly found in the lungs, with only 5% occurring outside the pulmonary system. Despite its common occurrence in the cervix, SCC can also develop in the ovaries, endometrium, vagina, and vulva. Primary carcinoma of the Bartholin's gland (BGC) represents a minute fraction of gynecological cancers, often presenting diagnostic challenges due to its deep-seated location. We present the case of a 43-year-old menopausal patient with familial cancer predisposition. She presented with a localized mass in the right Bartholin's gland and underwent excision surgery. Histological analysis confirmed a highly aggressive neuroendocrine carcinoma morphologically consistent with small cell neuroendocrine carcinoma. The patient underwent radiochemotherapy with cisplatin and etoposide, followed by pelvic and inguinal radiotherapy and vulvar brachytherapy. Imaging revealed metastatic lymph node dissemination, necessitating aggressive treatment. In conclusion, SCC of the BG is a rare and aggressive malignancy requiring multidisciplinary management for optimal outcomes. Further research is needed to establish standardized treatment protocols and improve prognosis.},
added-at = {2024-04-20T19:15:48.000+0200},
author = {Hajar, Medyouni and Jihane, Chouef and Oumaima, Siyouri and Samia, El Hakym and Samia, Mhirech and Lamiae, Amaadour and Karima, Oualla and Zineb, Benbrahim and Samia, Arifi and Nawfel, Mellas},
biburl = {https://www.bibsonomy.org/bibtex/29cd92f575af68f949e304bcbd257a6a8/ajmpr},
doi = {https://doi.org/10.5281/zenodo.10971995},
interhash = {3e8fb74fe5f7ea8855544175b30215b1},
intrahash = {9cd92f575af68f949e304bcbd257a6a8},
issn = {E-ISSN: 2992-4197; P-ISSN: 2992-4170},
journal = {African Journal of Medicine and Pharma Research },
keywords = {carcinoma cisplatin etoposide radiochemotherapy},
language = {English},
month = {Jan-Jun-2024},
number = 1,
pages = {1-4},
subjectarea = {Medical Oncology},
timestamp = {2024-04-20T19:19:39.000+0200},
title = {Small Cell Neuroendocrine Carcinoma of Bartholin's Gland: A Case Report},
url = {https://africanjmpr.com/docs/2024/jan-june-2024/AJMPR-01.pdf},
volume = 2,
year = 2024
}